This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
Dr. Richard Sautter accuses my recent editorial of a misinterpretation of the findings of a cooperative trial organized to evaluate the thrombolytic activity of urokinase in pulmonary embolism.The report did yield valuable data, and the immense amount of detailed work is admirable. What the editorial objected to can be summed up under two headings. First, thrombolytic agents such as streptokinase and urokinase have long been known to dissolve fresh clots in the vascular system. Dr. Sautter and his associates have notably contributed to this subject, having shown quite recently that the response of the fibrinolytic system to surgical stress varies from patient to patient, a subject in which my associates and I have been involved for a long time. Obviously, the defensive mechanisms of the body depend on many factors, and defective thrombolysis may well be an important factor in the formation and lysis of thromboemboli
de Takats G. The Urokinase-Pulmonary Embolism Trial. JAMA. 1974;227(10):1121. doi:10.1001/jama.1974.03230230013003
Customize your JAMA Network experience by selecting one or more topics from the list below.